MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pharming Group N.V.

< Previous 1 2 Next >
News headline image
Pharming Group announces third quarter 2026 revenues above market expectations
From Pharming Group N.V.
Via GlobeNewswire
Tickers PHAR
News headline image
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
From Pharming Group N.V.
Via GlobeNewswire
Tickers PHAR
News headline image
Pharming announces CEO transition
From Pharming Group N.V.
Via GlobeNewswire
Tickers PHAR
News headline image
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
From Pharming Group N.V.
Via GlobeNewswire
Tickers PHAR
News headline image
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
From Pharming Group N.V.
Via GlobeNewswire
News headline image
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
From Pharming Group N.V.
Via GlobeNewswire
News headline image
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports preliminary 2025 revenues and announces Investor Day
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group provides update on previously announced G&A expense reduction plan
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group promoted to the Euronext AMX® index
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports second quarter and first half 2025 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports first quarter 2025 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
From Pharming Group N.V.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story